x

Posted 01 February, 2024

ENZO BIOCHEM INC appointed Kara Cannon as new CEO

NYSE:ENZ appointed new Chief Executive Officer Kara Cannon in a 8-K filed on 01 February, 2024.


  On January 31, 2024, the board of directors (the "Board") of Enzo Biochem, Inc. (the "Company") appointed Kara Cannon to serve as the Chief Executive Officer of the Company and Patricia Eckert, CPA, to serve as the Chief Financial Officer of the Company, in each case, until her successor is duly elected and qualified.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of ENZO BIOCHEM INC
Health Care/Life Sciences • Biotechnology
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which engages in the manufacture, development and market of products and tools for clinical research, translational research, drug development and bioscience research. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in August 1976 and is headquartered in New York, NY.
Market Cap
$67.2M
View Company Details
ENZO BIOCHEM INC by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On January 31, 2024, the board of directors (the "Board") of Enzo Biochem, Inc. (the "Company") appointed Kara Cannon to serve as the Chief Executive Officer of the Company and Patricia Eckert, CPA, to serve as the Chief Financial Officer of the Company, in each case, until her successor is duly elected and qualified. Ms. Cannon previously served as the Company's interim Chief Executive Officer since her appointment to such position on September 5, 2023, as disclosed in a Current Report on Form 8-K filed by the Company on September 7, 2023. Prior to that, Ms. Cannon was the Company's Chief Operating Officer; she has been employed with the Company since 2011. Ms. Eckert previously served as the Company's interim Chief Financial Officer since November 14, 2022, as disclosed in a Current Report on Form 8-K filed by the Company on October 20, 2022. 


Each of Ms. Cannon's and Ms. Eckert's biographies is set forth in the Company's definitive proxy statement for its 2023 Annual Meeting of Shareholders (which was held on January 31, 2024) (the "2023 Annual Meeting"), filed with the Securities and Exchange Commission on December 21, 2023. Neither Ms. Cannon nor Ms. Eckert has any family relationships with any of the Company's directors or executive officers, and is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K.